Why has NICE said this?
NICE looks at how well treatments work in relation to how much they cost compared with other treatments available on the NHS. It applies special considerations to treatments that can extend the lives of people who are nearing the end of their life.
Ramucirumab does not provide enough benefit to patients to justify its high cost and did not qualify for the 'special considerations', so it was not recommended.